Article
Oncology
Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David D. Chang
Summary: The purpose of this study is to determine the impact of KRAS gene mutations on the efficacy of panitumumab monotherapy for metastatic colorectal cancer (mCRC). Through testing on 463 patients, it was found that 43% of patients had KRAS mutations. The results showed that panitumumab significantly improved overall survival and progression-free survival for patients with wild-type KRAS, while no significant efficacy was observed for patients with KRAS mutations. Therefore, KRAS status should be taken into account when selecting mCRC patients for panitumumab monotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Xiaofeng Jiang, Hengyu Zhao, Oliver Lester Saldanha, Sven Nebelung, Christiane Kuhl, Iakovos Amygdalos, Sven Arke Lang, Xiaojian Wu, Xiaochun Meng, Daniel Truhn, Jakob Nikolas Kather, Jia Ke
Summary: A deep learning model based on preoperative MRI scans was developed and validated to predict survival in patients with rectal cancer.
Article
Oncology
Anchuan Li, Tingxuan Huang, Rong Zheng, Pan Chi, Zhihua Li, Xiaozhong Wang, Benhua Xu
Summary: This study compared the survival outcomes, acute toxicities, and surgical complications in LARC patients who received preoperative chemoradiotherapy with triweekly XELOX or capecitabine. The results showed that both regimens had similar long-term survival outcomes, acute toxicities, and surgical complications.
Article
Medicine, General & Internal
Ning Li, Yuan Zhu, Lu-Ying Liu, Yan-Ru Feng, Wen-Ling Wang, Jun Wang, Hao Wang, Gao-Feng Li, Yuan Tang, Chen Hu, Wen-Yang Liu, Hua Ren, Shu-Lian Wang, Wei-Hu Wang, Yong-Wen Song, Yue-Ping Liu, Hui Fang, Yu Tang, Ning-Ning Lu, Bo Chen, Shu-Nan Qi, Xin-Fan Liu, Ye-Xiong Li, Jing Jin
Summary: The addition of oxaliplatin to postoperative capecitabine-based chemoradiotherapy did not improve treatment efficacy but increased the risk of severe acute toxic effects. Postoperative capecitabine with radiotherapy plays a fundamental role in the treatment of locally advanced rectal cancer.
Article
Oncology
Yi-Hsin Liang, Kuo-Hsing Chen, Yu-Yun Shao
Summary: Adding anti-EGFR mAb to first-line chemotherapy for KRAS wild-type mCRC is associated with significantly longer overall survival and time to treatment failure, especially in left-sided primary tumors.
Article
Oncology
John H. Strickler, Christel N. Rushing, Hope E. Uronis, Michael A. Morse, Donna Niedzwiecki, Gerard C. Blobe, Ashley N. Moyer, Emily Bolch, Renee Webb, Sherri Haley, Ace J. Hatch, Ivy P. Altomare, Gary B. Sherrill, David Z. Chang, James L. Wells, S. David Hsu, Jingquan Jia, S. Yousuf Zafar, Andrew B. Nixon, Herbert I. Hurwitz
Summary: The combination of cabozantinib and panitumumab has shown activity in patients with metastatic colorectal cancer, with dose modifications of cabozantinib improving tolerability. Further study is warranted to identify biomarkers for patient populations most likely to benefit.
Article
Surgery
R. E. Clifford, D. Harji, L. Poynter, R. Jackson, R. Adams, N. S. Fearnhead, D. Vimalachandran
Summary: The high mortality rate in rectal cancer patients with COVID-19 has prompted the adoption of alternative treatment strategies. The ReCaP study aims to study these variations and associated outcomes.
BRITISH JOURNAL OF SURGERY
(2021)
Article
Medicine, General & Internal
Xu Guan, Ran Wei, Runkun Yang, Zhao Lu, Enrui Liu, Zhixun Zhao, Haipeng Chen, Ming Yang, Zheng Liu, Zheng Jiang, Xishan Wang
Summary: Radiotherapy for rectal cancer is associated with an increased risk of developing cancer of the uterine corpus and ovarian cancer, leading to lower survival rates. Special attention should be given to reducing the occurrence of radiotherapy-associated SGMNs and improving prognosis.
Article
Medicine, General & Internal
Marwan G. Fakih, Lisa Salvatore, Taito Esaki, Dominik P. Modest, David P. Lopez-Bravo, Julien Taieb, Michalis V. Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
Summary: In this study, the combination of KRAS G12C inhibitor sotorasib and EGFR inhibitor panitumumab showed longer progression-free survival compared to standard treatment in patients with chemorefractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Deborah Schrag, Qian Shi, Martin R. Weiser, Marc J. Gollub, Leonard B. Saltz, Benjamin L. Musher, Joel Goldberg, Tareq Al Baghdadi, Karyn A. Goodman, Robert R. McWilliams, Jeffrey M. Farma, Thomas J. George, Hagen F. Kennecke, Ardaman Shergill, Michael Montemurro, Garth D. Nelson, Brian Colgrove, Vallerie Gordon, Alan P. Venook, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Amylou C. Dueck, Ethan Basch, George J. Chang, Harvey J. Mamon
Summary: Preoperative FOLFOX chemotherapy is as effective as preoperative chemoradiotherapy for locally advanced rectal cancer eligible for sphincter-sparing surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Hans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, Timothy Price, Ralf D. Hofheinz, Bernard Nordlinger, Jean-Francois Daisne, Jos Janssens, Baruch Brenner, Hans Reinel, Stephan Hollerbach, Karel Caca, Florian Fauth, Carla V. Hannig, John Zalcberg, Niall Tebbutt, Murielle E. Mauer, Sandrine Marreaud, Manfred P. Lutz, Karin Haustermans
Summary: The PETACC 6 trial investigated the addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative capecitabine in locally advanced rectal cancer, but found no improvement in efficacy and instead noted impaired tolerability and feasibility.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Wei-Wei Xiao, Min Li, Zhi-Wei Guo, Rong Zhang, Shao-Yan Xi, Xiang-Guo Zhang, Yong Li, De-Qing Wu, Yu-Feng Ren, Xiao-Lin Pang, Xiang-Bo Wan, Kun Li, Chun-Lian Zhou, Xiang-Ming Zhai, Zhi-Kun Liang, Qiao-Xuan Wang, Zhi-Fan Zeng, Hui-Zhong Zhang, Xue-Xi Yang, Ying-Song Wu, Ming Li, Yuan-Hong Gao
Summary: The PGS-LARC model is a reliable predictive tool for pCR in LARC patients, showing superior predictive performance compared to clinical factors. For patients with clinical complete response (cCR), the positive prediction value is 94.7%.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Review
Immunology
Tong Liu, Shuai Jiang, Xue Teng, Lu Zhong, Mengmeng Liu, Yao Jin, Mei Dong
Summary: In the treatment of metastatic colorectal cancer, there was no significant difference in overall survival, progression free survival, and response rate between cetuximab and panitumumab. However, there were differences in adverse reactions, with decreased incidence of paronychia in the panitumumab arm and decreased incidence of hypomagnesemia in the cetuximab arm.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
(2023)
Article
Medicine, General & Internal
Fei Li, Chi Zhang, Liping Xu, Sheng Zhang, Dongsheng Zhang, Yan Leng, Chenjiang Wu, Jiayan Chen, Xinchen Sun
Summary: Capecitabine-based nCRT in locally advanced rectal cancer patients showed high rates of survival and sphincter preservation. ypTNM stage and MRF status on magnetic resonance imaging were significant factors for patient prognosis.
Editorial Material
Medicine, General & Internal
Hanna K. Sanoff
Summary: The cure rate for nonmetastatic rectal cancer has been improving over the years, with surgery, radiation therapy, and chemotherapy being the routine treatment. Recent studies have shown that adding multiagent chemotherapy to radiation therapy before proctectomy can significantly increase the 3-year disease-free survival rate. However, this treatment approach also comes with severe long-term sequelae.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Hematology
Susanne Saussele, Marie-Paloma Krauss, Ruediger Hehlmann, Michael Lauseker, Ulrike Proetel, Lida Kalmanti, Benjamin Hanfstein, Alice Fabarius, Doris Kraemer, Wolfgang E. Berdel, Martin Bentz, Peter Staib, Maike de Wit, Martin Wernli, Florian Zettl, Holger F. Hebart, Markus Hahn, Jochen Heymanns, Ingo Schmidt-Wolf, Norbert Schmitz, Michael J. Eckart, Winfried Gassmann, Andrea Bartholomaeus, Antonio Pezzutto, Elisabeth Oppliger Leibundgut, Dominik Heim, Stefan W. Krause, Andreas Burchert, Wolf-Karsten Hofmann, Joerg Hasford, Andreas Hochhaus, Markus Pfirrmann, Martin C. Mueller
Article
Oncology
Oliver Gautschi, Nicholas Mach, Sacha I. Rothschild, Qiyu Li, Rolf A. Stahel, Alfred Zippelius, Richard Cathomas, Martin Frueh, Daniel C. Betticher, Solange Peters, Daniel Rauch, Jonas Feilchenfeldt, Lukas Bubendorf, Spasenija Savic, Rolf Jaggi, Elisabeth Oppliger Leibundgut, Carlo Largiader, Martin Brutsche, Christiane Pilop, Lukas Stalder, Miklos Pless, Adrian F. Ochsenbein
CLINICAL LUNG CANCER
(2015)
Article
Oncology
Marc Wehrli, Elisabeth Oppliger Leibundgut, Heinrich H. Gattiker, Markus G. Manz, Antonia M. S. Muller, Jeroen S. Goede
Article
Multidisciplinary Sciences
Sara Trabanelli, Mathieu F. Chevalier, Amaia Martinez-Usatorre, Alejandra Gomez-Cadena, Berengere Salome, Mariangela Lecciso, Valentina Salvestrini, Gregory Verdeil, Julien Racle, Cristina Papayannidis, Hideaki Morita, Irene Pizzitola, Camille Grandclement, Perrine Bohner, Elena Bruni, Mukul Girotra, Rani Pallavi, Paolo Falvo, Elisabeth Oppliger Leibundgut, Gabriela M. Baerlocher, Carmelo Carlo-Stella, Daniela Taurino, Armando Santoro, Orietta Spinelli, Alessandro Rambaldi, Emanuela Giarin, Giuseppe Basso, Cristina Tresoldi, Fabio Ciceri, David Gfeller, Cezmi A. Akdis, Luca Mazzarella, Saverio Minucci, Pier Giuseppe Pelicci, Emanuela Marcenaro, Andrew N. J. McKenzie, Dominique Vanhecke, George Coukos, Domenico Mavilio, Antonio Curti, Laurent Derre, Camilla Jandus
NATURE COMMUNICATIONS
(2017)
Article
Oncology
Susanne Saussele, Ruediger Hehlmann, Alice Fabarius, Sabine Jeromin, Ulrike Proetel, Sebastien Rinaldetti, Katharina Kohlbrenner, Hermann Einsele, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Elisabeth Oppliger Leibundgut, Dominik Heim, Stefan W. Krause, Wolf-Karsten Hofmann, Joerg Hasford, Markus Pfirrmann, Martin C. Mueller, Andreas Hochhaus, Michael Lauseker
Letter
Oncology
Susanne Burki, Evgenii Shumilov, Nicolas Bonadies, Johanna Flach, Myriam Legros, Yara Banz, Elisabeth Oppliger-Leibundgut, Martin Fiedler, Anne Angelillo-Scherrer, Alicia Rovo, Ulrike Bacher
LEUKEMIA & LYMPHOMA
(2018)
Article
Hematology
Julia Asp, Vibe Skov, Beatriz Bellosillo, Thomas Kristensen, Eric Lippert, Frank Dicker, Jiri Schwarz, Marzena Wojtaszewska, Lars Palmqvist, Susanna Akiki, Anni Aggerholm, Morten Tolstrup Andersen, Francois Girodon, Lasse Kjaer, Elisabeth Oppliger Leibundgut, Alessandro Pancrazzi, Marta Vorland, Hajnalka Andrikovics, Robert Kralovics, Bruno Cassinat, Margarida Coucelo, Aleksandar Eftimov, Karl Haslam, Rajko Kusec, Dorota Link-Lenczowska, Laurence Lode, Karolina Matiakowska, Dina Naguib, Filippo Navaglia, Guy Wayne Novotny, Melanie J. Percy, Andrey Sudarikov, Sylvie Hermouet, Niels Pallisgaard
ANNALS OF HEMATOLOGY
(2019)
Letter
Biophysics
Martin Sula, Ulrike Bacher, Elisabeth Oppliger Leibundgut, Behrouz Mansouri Taleghani, Urban Novak, Thomas Pabst
BONE MARROW TRANSPLANTATION
(2020)
Article
Hematology
Elisabeth Oppliger Leibundgut, Monika Haubitz, Bart Burington, Oliver G. Ottmann, Gary Spitzer, Olatoyosi Odenike, Michael A. McDevitt, Alexander Roeth, David S. Snyder, Gabriela M. Baerlocher
Summary: The telomerase inhibitor imetelstat showed rapid hematologic responses in the majority of patients within 3-6 months of treatment. Patients with additional somatic mutations might develop new mutations during treatment, but most still responded positively to imetelstat.
Article
Hematology
Stuart Scott, Ashley Cartwright, Sebastian Francis, Liam Whitby, A. Pia Sanzone, Andre Mulder, Sara Galimberti, Stephanie Dulucq, Carole Maute, Calogero Lauricella, Matthew Salmon, Susan Rose, Josh Willoughby, Nancy Boeckx, Niels Pallisgaard, Jacqueline Maier, Elisabeth O. Leibundgut, Hana Zizkova, Liuh Ling Goh, Chinh Duong, Wing F. Tang, Edmond Ma, Yogesh Shivakumar, Lan Beppu, Prasanthi Bhagavatula, Andrew Chantry
Summary: Measurement of BCR-ABL1 mRNA levels is critical in treatment protocols for chronic myeloid leukaemia, but interlaboratory variation remains an issue. This study demonstrated that RTddPCR can effectively detect BCR-ABL1 at different levels with improved linearity and reduced interlaboratory variation compared to RTqPCR.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Axel Karow, Monika Haubitz, Elisabeth Oppliger Leibundgut, Ingrid Helsen, Nicole Preising, Daniela Steiner, Tobias M. Dantonello, Roland A. Ammann, Jochen Roessler, Mutlu Kartal-Kaess, Alexander Roeth, Gabriela M. Baerlocher
Summary: The study found significant differences in telomere length and telomerase activity in lymphoblasts of patients with acute lymphoblastic leukemia. High-risk pediatric ALL patients had higher telomerase activity, and the telomerase inhibitor imetelstat showed significant dose-dependent apoptosis of B-ALL cells. Telomere length and telomerase activity may serve as complementary markers for identifying high-risk ALL patients, and telomerase inhibitors like imetelstat could enhance standard ALL treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Patrizia Froesch, Michael Mark, Sacha Rothschild, Qiyu Li, Gilles Godar, Corinne Rusterholz, Elisabeth Oppliger Leibundgut, Sabine Schmid, Ilaria Colombo, Yannis Metaxas, David Koenig, Cristiana Sessa, Oliver Gautschi, Martin Frueh
Summary: This study aimed to evaluate the toxicity and anticancer activity of the MEK inhibitor binimetinib in combination with cisplatin and pemetrexed in patients with KRAS-mutant NSCLC. The results showed no unexpected toxicity with this combination treatment in patients, but there was no early signal of significantly increased antitumor activity against lung cancer.
Meeting Abstract
Hematology
Ekaterina Rebmann Chigrinova, Naomi A. Porret, Gertrud Wiedemann, Martin Andres, Yara Banz, Myriam Legros, Matthias Pollak, Elisabeth Oppliger Leibundgut, Thomas Pabst, Ulrike Bacher
Article
Hematology
Gabriela M. Baerlocher, Monika Haubitz, Thomas R. Braschler, Claudio Brunold, Bart Burington, Elisabeth Oppliger Leibundgut, Ning Go
Meeting Abstract
Hematology
Monika Haubitz, Elisabeth Oppliger Leibundgut, Ingrid Helsen, Dania Hiltbrunner, Bart Burington, Oliver G. Ottmann, Gary Spitzer, Olatoyosi Odenike, Michael A. McDevitt, Alexander Roth, David S. Snyder, Gabriela M. Baerlocher